Trial Profile
A long-term, post-treatment safety follow-up, multi-center study in patients with type 2 diabetes mellitus from the GALLANT, GALLEX or ARMOR studies
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2019
Price :
$35
*
At a glance
- Drugs Tesaglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms G-PLUS
- Sponsors AstraZeneca
- 28 Aug 2006 Status change
- 29 Mar 2006 New trial record.